Key result
Diclofenac suppositories administered prior to transpapillary interventions reduced the incidence of acute post-ERCP pancreatitis by 3.6% (p=0.006).
Why the study?
The efficacy of nonsteroidal anti-inflammatory drugs in preventing pancreatitis following endoscopic retrograde interventions was uncertain.
Does diclofenac reduce the incidence of acute post-ERCP pancreatitis in patients undergoing transpapillary interventions?
Cohort (n=865)
No
Does diclofenac reduce the incidence of acute post-ERCP pancreatitis in patients undergoing transpapillary interventions?
Pre-procedural diclofenac suppositories significantly reduce the incidence of acute pancreatitis following endoscopic retrograde interventions.
Aim. To determine the efficacy of nonsteroidal anti-inflammatory drugs in preventing the development of pancreatitis following endoscopic retrograde interventions. Materials and methods. The study enrolled 865 patients who underwent transpapillary interventions for various hepatopancreatoduodenal diseases from 2019 to 2023. Patients in the main group (n = 470) were additionally prescribed Diclofenac suppositories (100 mg) 20–30 minutes prior to the procedure. Results. In the main group, acute post-ERCP pancreatitis developed 1.8 times less frequently than in the control group. Nonsteroidal anti-inflammatory drugs reduced the incidence of acute post-ERCP pancreatitis by 3.6% (p = 0.006). Conclusion. Nonsteroidal anti-inflammatory drugs decrease the incidence of acute post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Regardless of their application, additional measures for preventing complications are required. The role of nonsteroidal anti-inflammatory drugs in preventing complications following endoscopic retrograde interventions warrants further research in larger patient groups.
No takes yet. Share an insight, caveat, or question.
Dynko et al. (2024) conducted a cohort in Hepatopancreatoduodenal diseases requiring transpapillary interventions (n=865). Diclofenac suppositories vs. Control group (no diclofenac) was evaluated on Acute post-ERCP pancreatitis (ARR 3.6%, p=0.006). Diclofenac suppositories administered prior to transpapillary interventions reduced the incidence of acute post-ERCP pancreatitis by 3.6% (p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: